Acepodia, Inc.
Acepodia, Inc. operates as a clinical stage biotechnology company. The company engages in developing cell therapies with its antibody cell conjugation (ACC) platform technology to address cancer care. It develops AD2C targeting GPC3 for HCC which is in preclinical stage; ACE 1831 targeting CD20 that is in phase 1 clinical trial; ACE 2016 targeting EGFR, which is in Phase 1 clinical trial; ACE183 … Read more
Market Cap & Net Worth: Acepodia, Inc. (6976)
Acepodia, Inc. (TWO:6976) has a market capitalization of $217.84 Million (NT$7.21 Billion) as of March 18, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #17189 globally and #701 in its home market, demonstrating a -3.50% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Acepodia, Inc.'s stock price NT$12.40 by its total outstanding shares 581250554 (581.25 Million).
Acepodia, Inc. Market Cap History: 2023 to 2026
Acepodia, Inc.'s market capitalization history from 2023 to 2026. Data shows change from $601.70 Million to $217.84 Million (-36.39% CAGR).
Acepodia, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Acepodia, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
36.26x
Acepodia, Inc.'s market cap is 36.26 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $601.70 Million | $16.59 Million | -$817.32 Million | 36.26x | N/A |
Competitor Companies of 6976 by Market Capitalization
Companies near Acepodia, Inc. in the global market cap rankings as of March 18, 2026.
Key companies related to Acepodia, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Acepodia, Inc. Historical Marketcap From 2023 to 2026
Between 2023 and today, Acepodia, Inc.'s market cap moved from $601.70 Million to $ 217.84 Million, with a yearly change of -36.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$217.84 Million | -19.22% |
| 2025 | NT$269.67 Million | -12.03% |
| 2024 | NT$306.56 Million | -49.05% |
| 2023 | NT$601.70 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Acepodia, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $217.84 Million USD |
| MoneyControl | $217.84 Million USD |
| MarketWatch | $217.84 Million USD |
| marketcap.company | $217.84 Million USD |
| Reuters | $217.84 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.